Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.

Journal of Lipid Research
Sam J L van der TuinYanan Wang

Abstract

Recently, we showed in APOE*3-Leiden cholesteryl ester transfer protein (E3L.CETP) mice that anacetrapib attenuated atherosclerosis development by reducing (V)LDL cholesterol [(V)LDL-C] rather than by raising HDL cholesterol. Here, we investigated the mechanism by which anacetrapib reduces (V)LDL-C and whether this effect was dependent on the inhibition of CETP. E3L.CETP mice were fed a Western-type diet alone or supplemented with anacetrapib (30 mg/kg body weight per day). Microarray analyses of livers revealed downregulation of the cholesterol biosynthesis pathway (P < 0.001) and predicted downregulation of pathways controlled by sterol regulatory element-binding proteins 1 and 2 (z-scores -2.56 and -2.90, respectively; both P < 0.001). These data suggest increased supply of cholesterol to the liver. We found that hepatic proprotein convertase subtilisin/kexin type 9 (Pcsk9) expression was decreased (-28%, P < 0.01), accompanied by decreased plasma PCSK9 levels (-47%, P < 0.001) and increased hepatic LDL receptor (LDLr) content (+64%, P < 0.01). Consistent with this, anacetrapib increased the clearance and hepatic uptake (+25%, P < 0.001) of [(14)C]cholesteryl oleate-labeled VLDL-mimicking particles. In E3L mice that do not e...Continue Reading

References

May 12, 1975·Analytical Biochemistry·T G RedgraveC E West
Sep 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·M S Brown, J L Goldstein
May 1, 2004·Proceedings of the National Academy of Sciences of the United States of America·Kara N Maxwell, Jan L Breslow
Aug 7, 2004·Bioinformatics·James M Wettenhall, Gordon K Smyth
Apr 1, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·John S MillarDaniel J Rader
Sep 2, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·Marit WesterterpPatrick C N Rensen
Feb 8, 2007·Steroids·Yoav E Timsit, Masahiko Negishi
May 26, 2007·Journal of Lipid Research·Caroline C van der HoogtPatrick C N Rensen
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
May 10, 2008·Bioinformatics·Pan DuSimon M Lin
Aug 2, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·José W A van der HoornHans M G Princen
Nov 12, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Nov 19, 2010·The New England Journal of Medicine·Christopher P CannonUNKNOWN Determining the Efficacy and Tolerability Investigators
Feb 23, 2012·International Journal of Biological Sciences·Liwen ZhangAyesha Sitlani
Nov 7, 2012·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN dal-OUTCOMES Investigators
May 16, 2013·Circulation. Cardiovascular Quality and Outcomes·Ioannis KaralisJ Wouter Jukema
Oct 29, 2013·Annual Review of Pharmacology and Toxicology·Giuseppe Danilo NorataAlberico Luigi Catapano
Jan 16, 2014·Annual Review of Medicine·Evan A Stein, Frederick Raal
Apr 29, 2014·European Journal of Pharmacology·Thomas P RoddyDouglas G Johns
Aug 21, 2014·Journal of Lipid Research·Susan KühnastHans M G Princen
Mar 11, 2015·Nature Communications·Jimmy F P BerbéePatrick C N Rensen

❮ Previous
Next ❯

Citations

Nov 10, 2015·Translational Research : the Journal of Laboratory and Clinical Medicine·Nicola FerriMassimiliano Ruscica
Mar 18, 2016·Pharmacological Reviews·Philip J Barter, Kerry-Anne Rye
Mar 26, 2016·The Lancet. Diabetes & Endocrinology·Ezim Ajufo, Daniel J Rader
Nov 18, 2016·Expert Opinion on Drug Metabolism & Toxicology·Claudio Borghi, Arrigo F G Cicero
Dec 30, 2016·International Journal of Clinical Practice·Panagiotis AnagnostisDimitrios G Goulis
Feb 15, 2017·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·S C BergheanuJ W Jukema
Sep 18, 2015·Journal of Lipid Research·Philip J BarterKerry-Anne Rye
Sep 30, 2017·Diseases·Theodosios D FilippatosMoses S Elisaf
Dec 7, 2017·The EPMA Journal·Michał WicińskiGrzegorz Grześk
Dec 13, 2017·Expert Opinion on Drug Metabolism & Toxicology·Arrigo F G CiceroClaudio Borghi
Aug 31, 2018·Cardiovascular Research·Iwona CichaDidier Letourneur
Aug 12, 2017·Expert Opinion on Pharmacotherapy·Sheila A Doggrell
Jun 23, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Qian DengJingui Xue
Aug 28, 2019·Current Medicinal Chemistry·Olga PanagiotopoulouMarietta Charakida

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.